share_log

Innate Pharma Reported Q1 Revenue Of €6.6M Down From €26M YoY; Cash Position Of €113.9M

Benzinga ·  May 14 02:49
  • First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at AACR 2024
  • Progression of Sanofi-developed NK Cell Engager SAR443579/IPH6101 to Phase 2 in blood cancers
  • Five ASCO Annual Meeting 2024 abstracts:
    • Final TELLOMAK Phase 2 data for lacutamab in Mycosis Fungoides
    • Two posters on IPH6501, Innate's second generation ANKET in B‐cell Non-Hodgkin's Lymphoma
    • AstraZeneca to present poster on updated results for monalizumab from Phase 2 stage III unresectable NSCLC trial
    • Monalizumab SCLC Phase 2 MOZART trial poster
  • Cash position of €113.9 million1 as of March 31, 2024 (not including the €4.0 million payment to be received from Sanofi), anticipated cash runway into end 2025
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment